A Proactive Au interview with the CEO for Nyrada, James Bonnar is on YouTbe. There was some very good detail in there and the huge potential. Clinical phases are planned for late 2021, the two drugs are each targeting US$20B global markets and both are on track to be better products than what is on offer atm. It might take awhile for the market to wake up, but this is more likely to be closer to a $1B company in a years time. The news will come in due course.
Earlier this year Novartis paid US$9.7B for The Medicine Company and it's anti-cholesterol drug which was still in clinical trials. Nyrada's brain injury drug should be worth the same again.
NYR Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)